

ASX Announcement

Key Australian Patent for Recce's Broad-Spectrum Antibiotics

SYDNEY, Australia, 31 July 2018: Recce Pharmaceuticals Ltd (ASX:RCE) (**Company**), the Company developing a new class of broad spectrum synthetic antibiotics, today announced that Australian patent WO2016/077879 '*Copolymer and Method for Treatment of Bacterial Infection*', has been accepted for grant by the Australian Patent Office. The patent is the first of Recce's patent family 2 (Multi Drug Applications) and offers significant additional market monopolies to November 2034.

The Australian patent contains 34 claims, covering Recce's broad spectrum antibiotic compounds (herein RECCE[®] antibiotics), including its lead candidate RECCE[®] 327, with particular coverage of:

- Composition/method of manufacture of RECCE[®] antibiotics
- Use of RECCE[®] antibiotics for the treatment of bacterial infections in the blood (bacteraemia - sepsis), meninges, lungs, urinary tract, sinuses, skin, wounds and abscesses – caused by Gram-positive (G+) and Gram-negative (G-) bacteria, including in their superbug forms
- Prevention of bacterial infection from surgical procedures
- Administration of RECCE[®] antibiotics by oral, injection, inhalation and transdermal application

Examples of some of the G+, G- and superbug forms of common bacteria covered under the patent include *Pseudomonas aeruginosa*, *Neisseria meningitidis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Enterococcus* species, *Proteus* species, *Staphylococcus* species and *Streptococcus* species. These bacteria cause serious and at times life-threatening



ASX: RCE

Head Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

R&D Centre - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

infections such as septicaemia, meningitis, meningococcal disease, urinary tract infection, wound infections and pneumonia.

Recce's commercialisation strategy includes the expansion of its wholly-owned (without caveat), patent family estate. This newly awarded patent expands opportunities/protection of the Company's inventions, as represented through a series of granted and patent-pending families, including patent family 1 covering Methods of Manufacture, patent family 2 Multi-drug applications and patent family 3 Anti-viral uses. Family 2 patents filed in Europe and the USA are in their respective late stages of review.

Recce Executive Chairman, Dr Graham Melrose, said: "Recce's broad international strategy to protect and build its unique technology continues to significantly advance. This Australian patent, the first of many international applications under Patent Family 2, further strengthens the Company's overall IP position."

For further information please visit www.recce.com.au or contact:

Investor Relations

James Graham
Executive Director
Recce Pharmaceuticals Ltd
Tel: +61 (02) 8075 4585

Media (Australia)

Andrew Geddes
CityPR
Tel: +61 (02) 9267 4511

Media (International)

Sue Charles/Gemma Harris
Instinctif Partners
Tel: +44 (0)20 7866 7860
E: recce@instinctif.com

